文献速递免疫规划传染病防控与疫情报告

2023年10月至2024年1月加利福尼亚州实验室确诊流感的流感疫苗 interim 有效性

Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-02-29

利用加州2023年10月1日至2024年1月31日的免疫登记和实验室检测数据,比较病例组与对照组疫苗接种 odds,采用混合效应 logistic 回归估算 interim 流感疫苗有效性。≥6月龄人群总体 VE 为45%,6月龄至17岁儿童青少年为56%,18-49岁成人为48%,50-64岁为36%,≥65岁为30%。流感疫苗接种对实验室确诊流感提供了中等程度保护。

要点

  • ≥6月龄人群总体 interim VE 为45%。
  • 6月龄至17岁儿童青少年 VE 为56%,18-49岁为48%。
  • 50-64岁 VE 为36%,≥65岁为30%。

核心结论

  • 流感疫苗接种对婴儿、儿童、青少年和成人实验室确诊流感提供了中等程度保护,与部分既往流感季一致。
  • 所有≥6月龄且无接种禁忌者应每年接种流感疫苗,以减少流感疾病、重症流感及医疗资源压力。
  • 流感疫苗接种仍是预防流感的最佳方式。

研究设计与样本

  • 加州公共卫生部利用2023年10月1日至2024年1月31日期间收集的监测数据计算 interim 流感疫苗有效性。
  • 比较病例组(流感实验室检测阳性者)与对照组(流感实验室检测阴性者)的疫苗接种 odds。
  • VE 按1减去调整后 odds ratio 计算,采用混合效应 logistic 回归,年龄、种族和民族为固定效应,标本采集周和县为随机效应。

主要发现

  • 2023年10月1日至2024年1月31日期间,≥6月龄人群估计 VE 为45%。
  • 6月龄至17岁儿童和青少年估计 VE 为56%。
  • 18-49岁成人估计 VE 为48%。
  • 50-64岁人群估计 VE 为36%。
  • ≥65岁人群估计 VE 为30%。

关键数值与推荐

  • VE 计算方式为1减去调整后 odds ratio。
  • ≥6月龄人群总体 VE 为45%。
  • 6月龄至17岁儿童青少年 VE 为56%。
  • 18-49岁成人 VE 为48%。
  • 50-64岁人群 VE 为36%。

临床怎么用

  • 所有≥6月龄且无接种禁忌者应每年接种流感疫苗,以减少流感疾病、重症流感及医疗资源压力。
  • 流感疫苗接种仍是预防流感的最佳方式。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surveillance data can provide rapid, within-season influenza vaccine effectiveness (VE) estimates to guide public health recommendations. Mandatory reporting of influenza vaccine administration to California's immunization information registry began January 1, 2023, and mandatory reporting of all influenza laboratory test results, including negative results, was instituted in California on June 15, 2023. These data, collected by the California Department of Public Health during October 1, 2023-January 31, 2024, were used to calculate interim influenza VE against laboratory-confirmed influenza by comparing the odds of vaccination among case-patients (persons who received a positive influenza laboratory test result) and control patients (those who received a negative influenza laboratory test result). VE was calculated as 1 - adjusted odds ratio using mixed-effects logistic regression, with age, race, and ethnicity as fixed effects and specimen collection week and county as random effects. Overall, during October 1, 2023-January 31, 2024, estimated VE was 45% among persons aged ≥6 months, 56% among children and adolescents aged 6 months-17 years, 48% among adults aged 18-49 years, 36% among those aged 50-64 years, and 30% among those aged ≥65 years. Consistent with some previous influenza seasons, influenza vaccination provided moderate protection against laboratory-confirmed influenza among infants, children, adolescents, and adults. All persons aged ≥6 months without a contraindication to vaccination should receive annual influenza vaccination to reduce influenza illness, severe influenza, and strain on health care resources. Influenza vaccination remains the best way to prevent influenza.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Zhu S, Quint J, León TM, et al. Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38421946. doi:10.15585/mmwr.mm7308a4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。